Trail Gene Expression Analysis in Multiple Sclerosis Patients Publisher Pubmed



Nemati S¹ ; Taheri M¹ ; Movafagh A¹ ; Saberi M² ; Mirfakhraie R¹ ; Eftekharian MM^{3, 4} ; Shahrame AJ⁵ ; Rezagholizadeh A⁶ ; Sayad A¹ Show Affiliations
Source: Human Antibodies Published:2016

Abstract

Background: Multiple sclerosis (MS) as an autoimmune disorder in which the insulating covers of neurons in the Central Nervous System are destructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an immunomodulatory molecule to protect against T cells hyper activation. METHODS: In this Case-control study, we compare TRAIL gene expression in peripheral blood between 50 relapse remitting MS patients and 50 healthy controls by TaqMan Real time PCR. All the patients were negative for HLA-DRB1∗15 susceptible allele, normal serum vitamin D, responder to Interferon beta. All the health individuals were matched to patients. Also, we tried to find correlation between TRAIL gene expression and clinical characteristics of patients. RESULTS: No statistically significant difference was found in TRAIL mRNA expression between MS patients and controls (p > 0.05). There was no correlation in the TRAIL expression and age of onset, disease duration and Expanded Disability Status Scale of Kurtzke (EDSS). As IFN-b may have stimulatory effects on immunoregulatory function of TRAIL and all of our patients were treated with interferon beta and were responder, it lead to no significant change in TRAIL expression. We suggest comparing between responders and non-responders should be investigated. © 2015/2016-IOS Press and the authors. All rights reserved.